Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer.
CONCLUSION: Pertuzumab provided a more comprehensive inhibition of HER2-driven signalling pathways. When administered together with trastuzumab, pertuzumab represent a significant advancement for the treatment of HER2-positive metastatic breast cancer patients.
PMID: 23881722 [PubMed - as supplied by publisher]
Source: Advances in Therapy - Category: Drugs & Pharmacology Authors: De Mattos-Arruda L, Cortes J Tags: Adv Ther Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Docetaxel | Drugs & Pharmacology | HER2 | Herceptin | Study | Taxotere